PHXM — Phaxiam Therapeutics SA Balance Sheet
0.000.00%
- €0.92m
- €12.39m
- €1.33m
Annual balance sheet for Phaxiam Therapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 73.2 | 44.5 | 33.7 | 38.8 | 10.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.82 | 4.33 | 5.09 | 3.04 | 5.08 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 81.6 | 49.6 | 40 | 42.6 | 16.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 35.6 | 29.1 | 25.8 | 2.98 | 3.9 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 119 | 80.4 | 66.8 | 45.8 | 51.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19.9 | 29.3 | 20 | 11.7 | 15.3 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 33 | 53.9 | 43.9 | 22.3 | 25.7 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 85.6 | 26.5 | 22.8 | 23.5 | 25.6 |
Total Liabilities & Shareholders' Equity | 119 | 80.4 | 66.8 | 45.8 | 51.3 |
Total Common Shares Outstanding |